ArticleJournal of nanobiotechnology2026
Hydrogen-generating nanomodulators for metabolic repair and functional recovery in ovarian tissue transplantation.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Ischemia-reperfusion (I/R) injury occurring during ovarian tissue cryopreservation and transplantation (OTC-T) induces mitochondrial dysfunction and oxidative stress, leading to pronounced follicular loss and compromised graft performance-key challenges that limit transplantation success. Here, we present a hydrogen-releasing nanomodulator composed of potassium borohydride nanoparticles embedded within a thermosensitive hydrogel (KBH₄@Gel), designed to achieve sustained in situ hydrogen (H₂) generation for metabolic repair and ovarian function restoration. Upon local administration, the thermosensitive gel undergoes a sol-gel transition, encapsulating KBH₄ nanoparticles and enabling controlled H₂ release under mildly acidic, ischemia-mimicking conditions. Compared with free KBH₄ nanoparticles, KBH₄@Gel exhibits refined release kinetics and extended H₂ bioavailability, thereby providing long-term antioxidative protection. Mechanistic investigations demonstrate that KBH₄@Gel efficiently scavenges reactive oxygen species (ROS), preserves mitochondrial architecture, promotes angiogenesis at the graft site, and enhances ATP synthesis, ultimately reducing primordial follicle apoptosis and improving graft viability. This study introduces a precise and durable nanotherapeutic platform for metabolic repair and functional recovery in ovarian tissue transplantation, offering a broadly translatable strategy to mitigate I/R-induced injury across reproductive and other ischemic tissues.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.